Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

Acquired resistance to BRAF inhibitors often involves MAPK re‐activation, yet the MEK inhibitor trametinib showed minimal clinical activity in melanoma patients that had progressed on BRAF‐inhibitor therapy. Selective ERK inhibitors have been proposed as alternative salvage therapies. We show that E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Carlino, Matteo S., Todd, Jason R., Gowrishankar, Kavitha, Mijatov, Branka, Pupo, Gulietta M., Fung, Carina, Snoyman, Stephanie, Hersey, Peter, Long, Georgina V., Kefford, Richard F., Rizos, Helen
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2014
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528644/
https://ncbi.nlm.nih.gov/pubmed/24476679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.01.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados